{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/lipid-modification-cvd-prevention/goals-outcome-measures/qipp-options-for-local-implementation/","result":{"pageContext":{"chapter":{"id":"507f0f33-704f-5b79-813e-0ba2a367617e","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation","depth":2,"htmlHeader":"<!-- begin field 9d0a20ad-d6ed-4832-ae84-4f354b56855f --><h2>QIPP - Options for local implementation</h2><!-- end field 9d0a20ad-d6ed-4832-ae84-4f354b56855f -->","summary":null,"htmlStringContent":"<!-- begin item 9c4f4d8d-3cdb-4675-afd8-2b83ab9cd443 --><!-- begin field cb41325d-396f-446a-a450-ad0c5b49f379 --><ul><li>When a decision is made to prescribe a statin for primary or secondary prevention of cardiovascular disease, the NICE guideline on <a data-hyperlink-id=\"4ba06bff-2cc1-4e1f-aad2-aa940094b6ce\" href=\"http://www.nice.org.uk/guidance/cg181\">cardiovascular disease: risk assessment and reduction, including lipid modification</a> recommends using a statin of high intensity and low acquisition cost. The NICE guideline on <a data-hyperlink-id=\"8ef13021-4d4f-4d03-a463-aa940094b6f4\" href=\"http://www.nice.org.uk/guidance/cg71\">familial hypercholesterolemia</a> gives recommendations for people with this condition.</li><li>People with primary hypercholesterolaemia should be considered for ezetimibe treatment in line with the NICE technology appraisal guidance on <a data-hyperlink-id=\"f9ddbdf9-3e08-40d7-ac37-aa940094b714\" href=\"http://www.nice.org.uk/guidance/ta385\">ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia</a>.</li><li>People with primary hypercholesterolaemia or mixed dyslipidaemia should be considered for treatment with the PCSK9 inhibitors alirocumab or evolocumab in line with the NICE technology appraisal guidance on <a data-hyperlink-id=\"74fd09d3-72db-49be-9b43-aa940094b73e\" href=\"http://www.nice.org.uk/guidance/ta393\">alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia</a> and <a data-hyperlink-id=\"ccad8ab9-77a7-4b2d-bc93-aa940094b774\" href=\"http://www.nice.org.uk/guidance/ta394\">evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia</a>.</li><li>The NICE guideline on cardiovascular disease: risk assessment and reduction, including lipid modification recommends that bile acid sequestrants, nicotinic acid, fibrates and omega-3 fatty acid compounds should not generally be offered (see the guideline for details). It may be appropriate to use bile acid sequestrants, nicotinic acid or fibrates to treat familial hypercholesterolaemia in some circumstances (see the NICE guideline on <a data-hyperlink-id=\"7c0387f6-3997-4a82-b777-aa940094b7a7\" href=\"http://www.nice.org.uk/guidance/cg71\">familial hypercholesterolemia</a>).</li><li>Review and, if appropriate, optimise prescribing of lipid-modifying drugs including statins, ezetimibe, bile acid sequestrants, fibrates, nicotinic acid, omega-3 fatty acid compounds and PCSK9 inhibitors to ensure it is in line with NICE guidance.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/lipid-modification-cvd-prevention/references/\">NICE, 2017a</a>] </p><!-- end field cb41325d-396f-446a-a450-ad0c5b49f379 --><!-- end item 9c4f4d8d-3cdb-4675-afd8-2b83ab9cd443 -->","topic":{"id":"5303951d-71d9-506d-84ec-cbdd7ff3b93e","topicId":"dc4f1ad8-1fac-4248-9071-a622ca58dd2c","topicName":"Lipid modification - CVD prevention","slug":"lipid-modification-cvd-prevention","lastRevised":"Last revised in October 2020","chapters":[{"id":"7834a360-a716-55db-beef-e74397381f6b","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"4149ed5c-ad54-5793-8860-4b2f82d94427","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"184e9f02-cec5-5813-a428-f3b70683deda","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"0fd087eb-ba58-59e6-b641-2161dd021687","slug":"changes","fullItemName":"Changes"},{"id":"6e535866-055b-5f94-8d43-67cc6c3262a6","slug":"update","fullItemName":"Update"}]},{"id":"6952071a-0b87-50ea-af6b-c7589b86f9bd","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"3de1ddbe-7a0f-5384-9939-9a56d2251dfc","slug":"goals","fullItemName":"Goals"},{"id":"1a8df6be-f747-5d74-81cf-54d938d5944b","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"80c40530-2e39-55a1-910d-b5226d83d67a","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"e9906a94-72bf-5a9e-8e05-bb7b6841fec3","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"507f0f33-704f-5b79-813e-0ba2a367617e","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"c55b24f4-39a4-5919-8e05-5afc7b1ae5c6","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"f02326a5-5f6d-5026-9c8c-745fd760df23","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"f4e4cb23-7f1d-5543-a7a5-9316a25c589b","slug":"lipids-cardiovascular-health","fullItemName":"Lipids and cardiovascular health"}]},{"id":"5123c607-afa6-5c07-a939-547efe27b94c","fullItemName":"Management","slug":"management","subChapters":[{"id":"ec817edb-2375-548c-beb5-8afb1596d294","slug":"lipid-therapy-primary-prevention-of-cvd","fullItemName":"Scenario: Lipid therapy - primary prevention of CVD"},{"id":"4cd90098-cba6-5b78-994c-9fc173b4fb3f","slug":"lipid-therapy-secondary-prevention-of-cvd","fullItemName":"Scenario: Lipid therapy - secondary prevention of CVD"}]},{"id":"35a2dc51-a5b3-56bd-9a02-c420e08c1d0d","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"3e6af82a-f8f1-5d90-a988-05136fa101f3","slug":"statins","fullItemName":"Statins"}]},{"id":"238b503e-9352-5458-b356-3f6b521ef218","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"2dbe7113-fbe3-5fd2-bca1-2846dd9a39c8","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"fbe34d96-9294-5a30-8de1-1bc1f631ce69","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"df527078-d479-5b6f-aff8-247af2cdd323","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"1a8284ce-a2e5-59db-9d07-596f590c3ec3","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"9fe03c85-09a6-5232-8343-e77d91ad6145","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"d5bce13d-7bb2-5366-8bcc-28f538824ee4","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"f5e3b9df-860b-5c62-a358-a408038abc28","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"6952071a-0b87-50ea-af6b-c7589b86f9bd","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}